Compare VABK & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | KROS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.4M | 222.7M |
| IPO Year | 2013 | 2020 |
| Metric | VABK | KROS |
|---|---|---|
| Price | $50.44 | $11.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 8.0K | ★ 161.7K |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | 12.70 | ★ 146.00 |
| EPS | ★ 2.62 | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.35 | $9.69 |
| 52 Week High | $52.69 | $22.55 |
| Indicator | VABK | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 51.22 |
| Support Level | $46.42 | $10.82 |
| Resistance Level | N/A | $11.86 |
| Average True Range (ATR) | 1.33 | 0.54 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 54.71 | 43.25 |
Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.